| Ytd | -57.86% | |
| 1y | 37.54% |
| Open | 13.82 | Prev Close | 14.05 | Low | 12.56 | High | 14.07 | Mkt Cap | 302.64M |
| Vol | 163.85K | Avg Vol | 135.83K | EPS | -13.62 | P/E | N/A | Forward P/E | -0.73 |
| Beta | -0.48 | Short Ratio | 6.15 | Inst. Own | 58.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 16.72 | 200-d Avg | 20.77 | 1yr Est | 1.00 |
LYEL News
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYE
Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outpe
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-g
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) wi
Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advan
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10%
Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-g
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) wi